Trial reportRadiation oncology (London, England)2020
Stereotactic body radiotherapy (SBRT) for adrenal metastases of oligometastatic or oligoprogressive tumor patients.
Trial report in Radiation oncology (London, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 57 citations in OpenAlex.
- Risk factors of local control in adrenal metastases treated by stereotactic body radiation therapy - a systematic review and meta-analysis.Frontiers in oncology · 2023Pooled it
- Comparative effectiveness of thermal ablation, radiotherapy, and surgery for adrenal metastases: a multi-institutional cohort study.European radiology · 2026Article
- Margin for compensating displacement of adrenal gland metastasis and fiducial marker along with respiratory phase in real-time motion-tracking radiation therapy.Radiological physics and technology · 2025Article
- Efficacy of stereotactic body radiotherapy in hepatocellular carcinoma with adrenal metastases: a retrospective analysis.Journal of gastrointestinal oncology · 2025Article
- Insights on Oligometastatic Non-Small-Cell Lung Cancer.Cancers · 2025Review
- Privacy-friendly evaluation of patient data with secure multiparty computation in a European pilot study.NPJ digital medicine · 2024Article
- Adrenal Insufficiency following Stereotactic Ablative Radiotherapy (SAbR) of Adrenal Gland Metastases.Cancers · 2024Article
- Stereotactic Body Radiotherapy: is less fractionation more effective in adrenal and renal malignant lesions?World journal of urology · 2024Article
- Total dose, fraction dose and respiratory motion management impact adrenal SBRT outcome.Clinical and translational radiation oncology · 2024Article
- Article
- Radiation of bilateral adrenal metastases is associated with a high risk of primary adrenal insufficiency.Clinical endocrinology · 2023Article
- Robotic stereotactic body radiotherapy for the management of adrenal gland metastases: a bi-institutional analysis.Journal of cancer research and clinical oncology · 2023Article
- Stereotactic magnetic resonance-guided online adaptive radiotherapy of adrenal metastases combines high ablative doses with optimized sparing of organs at risk.Clinical and translational radiation oncology · 2023Article
- Two-institution results of Stereotactic Body Radiation Therapy (SBRT) for treating adrenal gland metastases from liver cancer.BMC cancer · 2023Article
- Lower fluorodeoxyglucose positron emission tomography maximum standardized uptake value may show a better response to stereotactic body radiotherapy of adrenals in oligometastatic disease.Contemporary oncology (Poznan, Poland) · 2023Article
- Stereotactic MR-Guided Radiotherapy for Adrenal Gland Metastases: First Clinical Results.Journal of clinical medicine · 2022Article
- PLA Renewable Bio Polymer Based Solid-State Gamma Radiation Detector-Dosimeter for Biomedical and Nuclear Industry Applications.Sensors (Basel, Switzerland) · 2022Article
- Predicting the benefit of stereotactic body radiotherapy of colorectal cancer metastases.Clinical and translational radiation oncology · 2022Article
- Short-term effectiveness and safety of CT-guided radioactive iodine-125 seed implantation for treatment of adrenal metastases.Journal of contemporary brachytherapy · 2022Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionLocal ablative treatment strategies are frequently offered to patients diagnosed with oligometastatic disease. Stereotactic body radiotherapy (SBRT), as ablative treatment option, is well established for lung and liver metastases, whereas for isolated adrenal gland metastases the level of evidence is scarce. MATERIAL AND
methodsThis single-institution analysis of oligometastatic or oligoprogressive disease was limited to patients who received SBRT to adrenal metastasis between 2012 and 2019. Patient, tumor, treatment characteristics, and dosimetric parameters were analyzed for evaluation of their effect on survival outcomes.
resultsDuring the period of review 28 patients received ablative SBRT to their adrenal gland metastases. Most common primary tumors were non-small cell lung cancers (46%) with most patients diagnosed with a single adrenal gland metastasis (61%), which occurred after a median time of 14 months. SBRT was delivered to a median biological effective dose at α/β of 10 (BED
conclusionSBRT for adrenal metastases resulted in promising LC with low toxicity. Treatment response appeared to be superior, if SBRT was applied with higher BED. As the close proximity of OARs often limits the application of sufficiently high doses, further dose escalations strategies and techniques should be investigated in future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.